The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Survival outcomes of early autologous stem cell transplant (ASCT) followed by lenalidomide, bortezomib, and dexamethasone (RVD) maintenance in patients with high-risk multiple myeloma (MM).
Jonathan L. Kaufman
Consultant or Advisory Role - Celgene; Keryx; Millennium; Novartis; Onyx
Research Funding - Celgene; Merck
Ajay K. Nooka
No relevant relationships to disclose
Samatha Muppidi
No relevant relationships to disclose
Leonard T. Heffner
Consultant or Advisory Role - Celgene; Millennium; Onyx
Charise Gleason
No relevant relationships to disclose
Lawrence Boise
No relevant relationships to disclose
Sagar Lonial
Consultant or Advisory Role - Bristol-Myers Squibb; Celgene; Merck; Millennium; Novartis; Onyx
Research Funding - Bristol-Myers Squibb; Celgene; Merck; Millennium; Novartis; Onyx